X

Trial Profile

A randomised phase III study of trastuzumab-docetaxel vs trastuzumab-vinorelbine as 1. line therapy for patients with metastatic HER2 positive breast cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms HERNATA

Most Recent Events

29 May 2015 Results of P95HER2 as a predictive marker of trastuzumab resistance were presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
17 Dec 2010 Results published in Journal of Clinical Oncology.
17 Dec 2010 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com